Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Newsfile Corp

05 Aug 2026, 19:47 UTC · 1h ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Capricor Therapeutics faces allegations that it implemented statistical analysis plan changes for Deramiocel without prior FDA agreement before resubmitting its Biologics License Application (BLA). — Lack of FDA alignment on clinical data analysis significantly increases the risk of regulatory rejection for a primary product candidate.
-0.80
2
The lawsuit claims there is a substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. — Directly threatens the commercial viability of the company's key therapy, which is a primary driver of company valuation.
-0.70
3
A securities class action lawsuit has been filed against Capricor Therapeutics alleging materially false or misleading statements regarding the prospects of Deramiocel. — Class action litigation creates financial liability and signals potential corporate governance or disclosure failures.
-0.50

Which stocks this story touches

6 related stories

Seeking Alpha
3h ago
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
- biotech
- clinical trials
- fda
Read

ROSEN, SKILLED INVESTOR C… — CAPR -1.00 | NewsImpactScreener

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

What matters in this story

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

What matters in this story

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised

72 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Notifies Roblox (RBLX) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

What matters in this story

Next reads from the same story arc

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

What matters in this story

Next reads from the same story arc

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised

72 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Notifies Roblox (RBLX) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now